1-(cyclohexylmethyl)urea | 5472-36-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: 1-(cyclohexylmethyl)urea
• 英文别名: Cyclohexylmethyl-harnstoff；cyclohexylmethyl-urea；Hexahydrobenzylharnstoff；(Cyclohexylmethyl)urea；cyclohexylmethylurea
• CAS: 5472-36-6
• 化学式: C₈H₁₆N₂O
• mdl: MFCD00086788
• 分子量: 156.228
• InChiKey: DZLLYADKCHLBMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  1-(cyclohexylmethyl)urea 在 盐酸 、 硝酸 、 溶剂黄146 、 锌 、 sodium nitrite 作用下， 生成 (叠氮甲基)环己烷
  参考文献：
  名称：

  Preparation of Alkyl Azides from Hydrazine Derivatives¹

  摘要：

  DOI：

  10.1021/jo01105a001
• 作为产物：
  描述：

  1-苄基-3-(环己基甲基)脲 在 钯 氢气 作用下， 以 溶剂黄146 为溶剂， 生成 1-(cyclohexylmethyl)urea
  参考文献：
  名称：

  A simple conversion of amines into monosubstituted ureas in organic and aqueous solvents

  摘要：

  A versatile and highly efficient synthesis of monosubstituted ureas is described. The reaction of an amine with 4-nitrophenyl-N-benzylcarbamate, followed by hydrogenolysis, provides the corresponding urea in high yield and purity. This carbamate can also be employed for the derivatization of water-soluble polyamines (e.g. aminoglycoside antibiotics), while other reagents (e.g, benzylisocyanate) fail to give the desired products in any significant yield. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(00)02289-9

文献信息

• 12-EPI PLEUROMUTILINS
  申请人：NABRIVA THERAPEUTICS AG

  公开号：US20160332963A1

  公开（公告）日：2016-11-17

  A compound selected from 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-sulfanyl)-acetyl]-12-epi-mutilins, or 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-oxy)-acetyl]-12-epi-mutilins, wherein 12-epi-mutilin is characterized in that the mutilin ring at position 12 is substituted by two substituents, the first substituent at position 12 of the mutilin ring is a methyl group which methyl group has the inverse stereochemistry compared with the stereochemistry of the methyl group at position 12 of the naturally occurring pleuromutilin ring, the second substituent at position 12 of the mutilin ring is a hydrocarbon group comprising at least one nitrogen atom and all other substituents of the mutilin ring having the same stereochemistry compared with the stereochemistry of the substituents at the corresponding positions in the naturally occurring pleuromutilin ring; optionally in the form of a salt and/or solvate, wherein the naturally occurring pleuromutilin is of formula processes for the preparation of such compounds and their use as pharmaceuticals.

  从14-O-[((烷基、环烷基、杂环烷基、杂环芳基或芳基)-硫基)-乙酰基]-12-epi-木替林，或14-O-[((烷基、环烷基、杂环烷基、杂环芳基或芳基)-氧基)-乙酰基]-12-epi-木替林中选择的一种化合物，其中12-epi-木替林的特征在于木替林环在位置12被两个取代基取代，木替林环在位置12的第一个取代基是一个甲基基团，该甲基基团的立体化学与天然存在的普鲁木替林环在位置12的甲基基团的立体化学相反，木替林环在位置12的第二个取代基是一个含有至少一个氮原子的碳氢基团，木替林环的所有其他取代基与天然存在的普鲁木替林环中相应位置的取代基的立体化学相同；可选地以盐和/或溶剂的形式存在，其中天然存在的普鲁木替林的化学式为 制备这类化合物的方法以及它们作为药物的用途。
• AZOLE COMPOUNDS
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1486490A1

  公开（公告）日：2004-12-15

  The present invention provides a compound represented by the formula (I) wherein R1 is a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an optionally substituted hydroxy group, an optionally substituted thiol group or an optionally substituted amino group, A is an optionally substituted cyclic amino group or -NR2-W-D wherein R2 is a hydrogen atom or an alkyl group, W is a bond or a divalent acyclic hydrocarbon group, and D is an optionally substituted cyclic group, an optionally substituted amino group or an optionally substituted acyl group, B is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, X is an oxygen atom, a sulfur atom or an optionally substituted nitrogen atom, and Y is a bond or a divalent acyclic hydrocarbon group, or a salt thereof, which is useful for the prophylaxis or treatment of diabetic neuropathy and the like.

  本发明提供了一种由以下式（I）表示的化合物， 其中R1是氢原子、卤原子、可选择取代的碳氢基团、可选择取代的杂环基团、可选择取代的羟基、可选择取代的硫醇基团或可选择取代的氨基， A是可选择取代的环氨基团或-NR2-W-D，其中R2是氢原子或烷基，W是键或二价的非环烃基团，D是可选择取代的环基团、可选择取代的氨基团或可选择取代的酰基团， B是可选择取代的碳氢基团或可选择取代的杂环基团， X是氧原子、硫原子或可选择取代的氮原子，以及 Y是键或二价的非环烃基团，或其盐，用于预防或治疗糖尿病性神经病变等。
• One-Pot, Solvent-Free Access to Unsymmetrical Ureas by Palladium-Catalysed Reductive Alkylation Using Molecular Hydrogen
  作者：Tharwat Mohy El Dine、Simon Chapron、Marie-Christine Duclos、Nicolas Duguet、Florence Popowycz、Marc Lemaire

  DOI：10.1002/ejoc.201300642

  日期：2013.8

  Palladium-catalysed reductive alkylation of monosubstituted ureas has been studied in the presence of aldehydes and using molecular hydrogen as a clean reductant. Unsymmetrical N,N′-disubstituted ureas were formed in good to excellent isolated yields (60–93 %) without the production of salt waste. This reaction was incorporated to a one-pot, solvent-free sequence involving the alkylation of monosubstituted

  在醛的存在下并使用分子氢作为清洁还原剂，研究了钯催化的单取代脲的还原烷基化。不对称的 N,N'-二取代脲以良好至极好的分离产率 (60-93%) 形成，而不会产生盐废物。该反应被纳入一锅、无溶剂的序列中，包括从相应的胺原位生成的单取代脲的烷基化。
• M3 muscarinic acetylchoine receptor antagonists
  申请人：Busch-Petersen Jakob

  公开号：US20070185148A1

  公开（公告）日：2007-08-09

  Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.

  提供了肌碱乙酰胆碱受体拮抗剂及其使用方法。
• PYRROLOPYRIDINE INHIBITORS OF KINASES
  申请人：Florjancic Alan S.

  公开号：US20110015173A1

  公开（公告）日：2011-01-20

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R 1a , R 1b , R 1c , X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.

  本发明涉及公式（I）的化合物或药用可接受的盐，其中R1a、R1b、R1c、X和Y在描述中有定义。本发明还涉及含有上述化合物的组合物，该组合物对抑制Cdc7等激酶以及治疗癌症等疾病有用。